Source:http://linkedlifedata.com/resource/pubmed/id/16268467
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2005-11-4
|
| pubmed:abstractText |
Bridging anticoagulation with low-molecular-weight heparin (LMWH) is common in patients who require temporary interruption of warfarin before surgery or a procedure, but whether such patients have a residual anticoagulant effect just before a procedure is not known. Consecutive patients who received bridging anticoagulation with LMWH had anti-Xa levels measured just before a procedure. The proportion of patients with a residual anticoagulant effect, defined as an anti-Xa level > or = 0.10 IU/ml, was determined. Multivariable regression analysis identified predictors of a residual anticoagulant effect, expressed as an odds ratio (OR) and corresponding 95% confidence interval (CI). A pre-procedure residual anticoagulant effect was detected in 12 of 73 (16%) patients overall, in 11 of 37 (30%) patients who received therapeutic-dose LMWH, and in 1 of 36 patients (3%) who received low-dose LMWH. Receiving therapeutic-dose LMWH (OR = 118.8; 95% CI: 5.8, 999.9), and increasing age (OR = 4.0; 95% CI: 1.3, 12.5) were predictors of a residual pre-procedure anticoagulant effect. In patients who require bridging anticoagulation with LMWH, a residual anticoagulant effect from LMWH is detected in 1 of 6 patients, and receiving therapeutic-dose LMWH is the strongest predictor of such an effect.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
0340-6245
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
94
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
528-31
|
| pubmed:meshHeading |
pubmed-meshheading:16268467-Age Factors,
pubmed-meshheading:16268467-Aged,
pubmed-meshheading:16268467-Aged, 80 and over,
pubmed-meshheading:16268467-Anticoagulants,
pubmed-meshheading:16268467-Blood Coagulation Disorders,
pubmed-meshheading:16268467-Body Weight,
pubmed-meshheading:16268467-Factor Xa,
pubmed-meshheading:16268467-Female,
pubmed-meshheading:16268467-Hemorrhage,
pubmed-meshheading:16268467-Heparin, Low-Molecular-Weight,
pubmed-meshheading:16268467-Humans,
pubmed-meshheading:16268467-Male,
pubmed-meshheading:16268467-Middle Aged,
pubmed-meshheading:16268467-Preoperative Care,
pubmed-meshheading:16268467-Risk Factors,
pubmed-meshheading:16268467-Surgical Procedures, Operative,
pubmed-meshheading:16268467-Time Factors,
pubmed-meshheading:16268467-Treatment Outcome,
pubmed-meshheading:16268467-Warfarin
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery.
|
| pubmed:affiliation |
Department of Medicine and St. Joseph's Heathcare, McMaster University, Hamilton, Canada. jdouket@mcmaster.ca
|
| pubmed:publicationType |
Journal Article
|